ZYMEDI
Zymedi is a pharmaceutical company that develops drugs for life-threatening diseases.
ZYMEDI
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2019-12-01
Address:
Ansan, Inch'on-jikhalsi, South Korea
Country:
South Korea
Website Url:
http://www.zymedi.com
Total Employee:
11+
Status:
Active
Contact:
+82 32 822 8376
Email Addresses:
[email protected]
Technology used in webpage:
Euro South Korean Server Location
Similar Organizations
ARTham Therapeutics
ARTham Therapeutics is a biopharmaceutical company that delivers drugs to help patients.
Iol Chemicals & Pharmaceutical
Iol Chemicals & Pharmaceutical is a generic pharmaceutical company specializing in various therapeutic categories.
PRD Therapeutics
PRD Therapeutics is a pharmaceutical company that develops medicines for different metabolic diseases.
Surface Ophthalmics
Surface Ophthalmics is a pharmaceutical company that develops therapeutics for the treatment of ocular diseases.
Investors List
Company K Partners
Company K Partners investment in Venture Round - Zymedi
IMM Investment
IMM Investment investment in Venture Round - Zymedi
Official Site Inspections
http://www.zymedi.com Semrush global rank: 10.87 M Semrush visits lastest month: 198
- Host name: 211.115.73.20
- IP address: 211.115.73.20
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "Zymedi"
Zymedi - Crunchbase Company Profile & Funding
Zymedi has 2 investors including Company K Partners and IMM Investment. When was the last funding round for Zymedi? Zymedi closed its last funding round on Jan 1, 2021 from a Venture โฆSee details»
Zymedi - LinkedIn
Zymedi is a clinical-stage biopharmaceutical company focused on transforming the role of ARSs (Aminoacyl-tRNA Synthetases) as a novel target for discovering and developing treatments for โฆSee details»
Zymedi 2025 Company Profile: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Zymedi. Use the PitchBook Platform to explore the full profile.See details»
[Press Release] Zymedi, in collaboration with the German โฆ
Jan 22, 2025 With support from KIAT, the synergy between Zymedi, Yonsei University, and Evotec will accelerate the development of groundbreaking treatments for these high-unmet โฆSee details»
Zymedi Co. Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
The CRADA between Zymedi and the NHLBI will enable the organizations to collaborate together to advance the development of ZMA001. Zymedi will work with clinical investigators and โฆSee details»
ZYMEDI - BIO CEO & Investor Conference | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services.See details»
Zymedi | VentureRadar
At ZYMEDI we are putting our extensive knowledge of aminoacyl-tRNA synthetase (ARS) science to work to transform the next generation of drug discovery. Focused on the most challenging โฆSee details»
Zymedi - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 4, 2025 Zymedi - Developer of therapeutics for multiple diseases. Raised a total funding of $29.5M over 2 rounds from 8 investors. Founded by Sunghoon Kim in the year 2019. Zymedi โฆSee details»
์์ด๋ฉ๋ ์ต๊ณ ๊ฐ๋ฐ์ฑ ์์์ ๊ถํ์ ๋ฐ์ฌ ์์ - Zymedi
Jul 1, 2022 ์์ด๋ฉ๋๋ ์ ์ ์ต๊ณ ๊ฐ๋ฐ์ฑ ์์(CDO, ๋ถ์ฌ์ฅ)๋ก ๊ถํ์ ์ ์ผ๋์ ์ฝ Biological Research ๊ทธ๋ฃน์ฅ์ ์์ ํ์ต๋๋ค. ๊ถํ์ ๋ถ์ฌ์ฅ์ ์ฑ๊ท ๊ด๋ํ๊ต ์๋ฌผํ๊ณผ๋ฅผ ์กธ์ ํ์ผ๋ฉฐ ์์ธ๋ํ๊ต์์ ์ฝํ๋ฐ์ฌ๋ฅผ ์ทจ๋ํ์ต๋๋ค. 1996๋ ๋ถํฐ โฆSee details»
Attended and presented at Songdo Networking Day ์ก๋ ... - Zymedi
Feb 13, 2025 Networking Day for Songdo-based universities was held on the 13th at the Gyeongwonjae Ambassador Incheon Arirang Hall. The event, organized to foster exchanges โฆSee details»
Zymedi announced their collaboration with the National Heart, โฆ
Jul 3, 2023 Zymedi will work with clinical investigators and researchers of the Intramural NIH PAH Translational Research Team to conduct a Phase 1, First-in-Human Clinical Trial in โฆSee details»
Antibody Treatment Granted Orphan Drug Designation Status for โฆ
Jul 30, 2024 The US Food and Drug Administration (FDA) has granted Orphan Drug designation to ZMA001, an antibody therapy developed by Zymedi, for the treatment of pulmonary arterial โฆSee details»
News & Trend - Zymedi
[The Korea Economic Daily | Reporter Woosang Lee] ZYMEDI's drug candidate for pulmonary arterial hypertension (PAH) has been selected as an Outstanding Project in the National New โฆSee details»
Zymedi announced their collaboration with the National
Mar 7, 2023 SEOUL, South Korea, July 2, 2023 /PRNewswire/ -- Today Zymedi, a Korean biotech venture-backed company, announced the signing of a clinical Cooperative Research โฆSee details»
FDA Grants Orphan Drug Designation to ZMA001 for Pulmonary โฆ
Aug 1, 2024 The FDA has granted orphan drug designation to ZMA001 (Zymedi), a first-in-class antibody for pulmonary arterial hypertension (PAH). ZMA001 is a human monoclonal antibody โฆSee details»
Zymedi Relocates to a New Office ์์ด๋ฉ๋ New ์คํผ์ค ์ด์
Nov 22, 2024 Zymedi has successfully completed its move to a new office. The new space includes work areas, meeting rooms, and relaxation spaces to enhance productivity and โฆSee details»
ZM001 for PAH gets FDA orphan drug designation
Aug 2, 2024 The U.S. Food and Drug Administration (FDA) has given orphan drug designation to ZM001, a first-in-class investigational antibody from Zymedi for pulmonary arterial โฆSee details»
ZMA-001 by Zymedi for Pulmonary Arterial Hypertension: โฆ
ZMA-001 is under clinical development by Zymedi and currently in Phase I for Pulmonary Arterial Hypertension.See details»
[Press Release] Zymediโs ZMA001 Selected as an Outstanding โฆ
Dec 11, 2024 Zymedi announced on the 11th that its Phase 1 clinical research project for ZMA001, a novel drug candidate for the treatment of pulmonary arterial hypertension (PAH), โฆSee details»
ZMP201 (C-VAX) - Zymedi
The robust physicochemical properties of ZMP201 such as high thermostability, solubility as well as lack of local and systemic toxicity supports its potential as an immune stimulatory platform โฆSee details»